海特生物授权公司管理层启动境外发行股份（H股）并在香港联交所上市相关筹备工作

Core Viewpoint - The company, Hite Bio, announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy, accelerate overseas business development, and improve its international brand image [1] Group 1: Strategic Objectives - The company aims to deepen its global strategic layout and accelerate the development of its overseas business [1] - The initiative is part of a broader strategy to enhance the company's international brand image and create a diversified capital operation platform [1] - The move is expected to strengthen the company's overseas financing capabilities, contributing to high-quality development [1] Group 2: Implementation Plans - The board of directors has authorized the management team to initiate preliminary preparations for the H-share listing [1] - The company plans to discuss specific progress on the H-share listing with relevant intermediary institutions [1] - Details regarding the H-share listing have not yet been finalized [1]